Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|August 28, 2015
INTERLAB has Changed its Company Name to synlab Pharma Institute
Author(s)Company Press Release
Advertisement
In 2014 synlab services GmbH purchased INTERLAB GmbH central lab services – worldwide (INTERLAB). In September, INTERLAB merged with synlab Umweltinstitut GmbH, and consequently all documentation carries the synlab logo and will refer to the synlab pharma institute, Munich location, a division of synlab Umweltinstitut GmbH.
Please note that Dr. Hermann Schulz, Chief Executive Officer of INTERLAB until August 31st, 2015, will continue as a Legal Representative (“Prokurist”) of synlab Umweltinstitut GmbH. He will also head the synlab pharma institute as its Executive Vice President.
INTERLAB and synlab have been successfully cooperating since 2004. Hence, no impact on the day to day business or on the handling of study samples is to be expected. Our address, shipping logistics, and contractual terms shall not undergo any modifications. Although email addresses will switch form name@interlab.de to name@synlab.com your messages will automatically be re-routed.
As the new contractual partner, synlab Umweltinstitut GmbH shall overtake all duties and responsibilities of INTERLAB. Although invoices will be issued by synlab Umweltinstitut GmbH (using their tax ID: DE 195 993 312) the bank account at Deutsche Bank AG MuÌnchen will remain unchanged by the moment.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5